Press release
Ivonescimab Demonstrates Significant First-Line Advantage in NSCLC at ESMO 2025
In a highly anticipated first-line study presented at ESMO 2025, the bispecific antibody Ivonescimab (PD-1×VEGF) developed by Akeso Biopharma and Summit Therapeutics achieved a 40% reduction in risk of disease progression or death compared to the PD-1 inhibitor Tislelizumab (brand name Tevimbra) plus chemotherapy in previously untreated squamous non-small-cell lung cancer (NSCLC) in the HARMONi-6 trial.
The trial, conducted in a Chinese patient population, showed a median progression-free survival (PFS) of 11.1 months with Ivonescimab plus chemotherapy, compared to 6.9 months with Tislelizumab plus chemotherapy, reflecting an improvement of around 4.2 months. In patients with PD-L1 expression below 1%, Ivonescimab achieved a 45% increase in median PFS, indicating potential efficacy across a wide range of biomarker profiles.
While overall-survival (OS) data remain immature, the companies expressed optimism given a durable median duration of response of 11.2 months with Ivonescimab versus 8.4 months with Tislelizumab. A separate ongoing global trial, HARMONi-3, is comparing Ivonescimab to the market-leading Pembrolizumab (Keytruda) in both squamous and non-squamous NSCLC and will include ex-China populations, with squamous read‐out expected next year and non-squamous in 2027.
Unlock the future of NSCLC therapies, explore comprehensive market insights, epidemiology, and forecasts through 2034 today!
https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
About the Market Opportunity & DelveInsight Reports
In light of this emerging data, it is timely to note several recently published reports by DelveInsight that are highly relevant for NSCLC stakeholders:
• Non-Small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology and Market Forecast - 2034
• NSCLC Pipeline Insight - 2025: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• NSCLC Epidemiology Forecast - 2034: https://www.delveinsight.com/report-store/non-small-cell-lung-carcinoma-nsclc-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
The NSCLC market size in the 7 major markets (7MM) is projected to increase from USD 32,442 million in 2025, growing at a robust CAGR of 8%, and is expected to reach USD 64,819 million by 2034.
What NSCLC Market report provide and deliver:
• Epidemiology insight: Detailed breakdowns of incidence and prevalence of NSCLC by region (United States, EU5, Japan) and by biomarker sub-segments (eg. EGFR, KRAS, PD-L1).
• Market dynamics: Analysis of current and emerging treatments, treatment patterns, competitive landscape, and unmet needs in NSCLC.
• Forecasting & strategic intelligence: Sales forecasts, pipeline assessments, market entry strategies, company profiling, and growth opportunities across 2020-2034.
With the demonstration of a meaningful PFS benefit by Ivonescimab in a first-line NSCLC setting, the relevance of such market intelligence is elevated: pharmaceutical companies, investors, and healthcare decision-makers can leverage these reports to evaluate competitive positioning, forecast market share shifts, and inform R&D or commercial strategies.
Stay ahead in NSCLC research, access detailed market trends, patient epidemiology, and growth forecasts up to 2034 now!
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Conclusion:
The presentation of the HARMONi-6 results by Akeso & Summit at ESMO 2025 marks a promising development in front-line NSCLC treatment. Should further data confirm a survival benefit and apply broadly beyond China, Ivonescimab has potential to reshape standard-of-care in squamous and non-squamous NSCLC. Coupled with rich market analytics provided by DelveInsight, stakeholders are well positioned to interpret and act upon the evolving NSCLC landscape.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ivonescimab Demonstrates Significant First-Line Advantage in NSCLC at ESMO 2025 here
News-ID: 4264757 • Views: …
More Releases from DelveInsight Business Research
Quince Therapeutics Reports Favorable iDSMB Safety Review for eDSP in Ongoing Ph …
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late stage biotechnology company focused on leveraging a patient's own biology to treat rare diseases, announced that its ongoing pivotal Phase 3 trial of encapsulated dexamethasone sodium phosphate (eDSP) in patients with Ataxia Telangiectasia has passed a key safety milestone. The independent data and safety monitoring board (iDSMB) conducted a pre planned safety review and found no safety concerns, recommending the study continue without…
Endogenous Cushing's Syndrome Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Endogenous Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Endogenous Cushing's Syndrome, historical and forecasted epidemiology as well as the Endogenous Cushing's Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Endogenous Cushing's Syndrome, offering comprehensive insights into the Endogenous Cushing's Syndrome revenue trends,…
Lamellar Ichthyosis Market to Experience Notable Growth in Forecast Span by 2034 …
DelveInsight's "Lamellar Ichthyosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lamellar Ichthyosis, historical and forecasted epidemiology as well as the Lamellar Ichthyosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Lamellar Ichthyosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lamellar Ichthyosis Market Forecast
https://www.delveinsight.com/sample-request/lamellar-ichthyosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Global Anti-retropulsion Devices Market to grow at a CAGR of 6.69% by 2032, Eval …
According to DelveInsight's analysis, The rising demand for anti-retropulsion devices is mainly driven by the increasing incidence of kidney stones, often associated with factors like dehydration. Additionally, the growing prevalence of risk factors such as benign prostatic hyperplasia (BPH), obesity, and sedentary lifestyles-which significantly contribute to kidney stone formation-further supports market growth. Advances in anti-retropulsion device technology, coupled with ongoing R&D initiatives by key industry players, are also playing a…
More Releases for NSCLC
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.
With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
Global cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer.
Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how…
